The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study.
Nikita V LomakinBulat A BakirovDenis N ProtsenkoVadim I MazurovGaziyavdibir H MusaevOlga M MoiseevaElena S PasechnikVladimir V PopovElena A SmolyarchukIvan G GordeevMikhail Yu GilyarovDarya S FominaAnton I SeleznevYulia N LinkovaEkaterina A DokukinaAnna V EremeevaPolina P PukhtinskaiaMaria A MorozovaArina V Zinkina-OrikhanAnton A LutckiiPublished in: Inflammation research : official journal of the European Histamine Research Society ... [et al.] (2021)
The trial is registered at the US National Institutes of Health (ClinicalTrials.gov; NCT04397562).
Keyphrases
- phase iii
- double blind
- mechanical ventilation
- placebo controlled
- acute respiratory distress syndrome
- clinical trial
- phase ii
- intensive care unit
- public health
- healthcare
- sars cov
- phase ii study
- respiratory failure
- mental health
- study protocol
- quality improvement
- health information
- extracorporeal membrane oxygenation
- open label
- human health
- randomized controlled trial
- health promotion
- cross sectional
- risk assessment
- radiation therapy
- climate change